Literature DB >> 1759832

Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers.

B R Meyers1, P Wilkinson, M H Mendelson, S Walsh, C Bournazos, S Z Hirschman.   

Abstract

The pharmacokinetics of ampicillin-sulbactam in elderly subjects (65 to 85 years; group 3, n = 8), compared with those in middle-aged (41 to 64 years; group 2, n = 8) and younger (20 to 40 years; group 1, n = 8) subjects, were investigated. A single 2-g dose of ampicillin combined with 1 g of sulbactam in 60 ml of intravenous solution was administered to each subject over a 30-min period. Blood and urine samples were taken at baseline and serially over an 8.5-h period following the infusion. Ampicillin and sulbactam concentrations were assayed by high-performance liquid chromatography on a reversed-phase C-8 column. The mean levels in serum of both ampicillin and sulbactam were significantly higher for samples from group 3: for ampicillin from 1 through 8.5 h, and for sulbactam for the same time interval except at 5.5 h (P less than or equal to 0.05). The mean urinary excretion of both ampicillin and sulbactam was lowest, and urinary concentrations were highest in group 3. The areas under the serum drug concentration-time curve, the half-lives, and the maximum concentrations in serum were greatest, while the total clearance was lowest, for group 3 for both ampicillin and sulbactam. These results are consistent with a prolongation of antimicrobial activity of ampicillin-sulbactam in the elderly compared with that in younger subjects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759832      PMCID: PMC245332          DOI: 10.1128/AAC.35.10.2098

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 2.  Pharmacokinetics of antimicrobial agents in the elderly.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Rev Infect Dis       Date:  1987 Mar-Apr

Review 3.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

Review 4.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

Review 5.  Pharmacokinetics of sulbactam/ampicillin in humans: a review.

Authors:  G Foulds
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

6.  Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.

Authors:  J A Retsema; A R English; A Girard; J E Lynch; M Anderson; L Brennan; C Cimochowski; J Faiella; W Norcia; P Sawyer
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

7.  Pharmacokinetics of ceftazidime in elderly patients and young volunteers.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Scand J Infect Dis       Date:  1984

8.  Pharmacokinetics of cefoperazone in ambulatory elderly volunteers compared with young adults.

Authors:  B R Meyers; M H Mendelson; R G Deeter; E Srulevitch-Chin; M T Sarni; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

9.  Pharmacokinetics of intravenous antibiotics in acutely ill elderly patients.

Authors:  M Jonsson; M Walder
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

Review 10.  Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.

Authors:  B R Meyers; P Wilkinson
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

View more
  16 in total

1.  Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug Development.

Authors:  Jian Wang; Shaun S Kumar; Catherine M Sherwin; Robert Ward; Gerri Baer; Gilbert J Burckart; Yaning Wang; Lynne P Yao
Journal:  Clin Pharmacol Ther       Date:  2019-02-10       Impact factor: 6.875

2.  A Naturally Occurring Single Nucleotide Polymorphism in a Multicopy Plasmid Produces a Reversible Increase in Antibiotic Resistance.

Authors:  Alfonso Santos-Lopez; Cristina Bernabe-Balas; Manuel Ares-Arroyo; Rafael Ortega-Huedo; Andreas Hoefer; Alvaro San Millan; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

3.  Small-plasmid-mediated antibiotic resistance is enhanced by increases in plasmid copy number and bacterial fitness.

Authors:  Alvaro San Millan; Alfonso Santos-Lopez; Rafael Ortega-Huedo; Cristina Bernabe-Balas; Sean P Kennedy; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

4.  Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.

Authors:  Brian J Werth; Laura M Shireman
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

5.  β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

6.  Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.

Authors:  M B Marques; E S Brookings; S A Moser; P B Sonke; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 8.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

Review 9.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 10.  Ampicillin/sulbactam: current status in severe bacterial infections.

Authors:  Petros I Rafailidis; Eleni N Ioannidou; Matthew E Falagas
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.